PT2938597T - Sais sulfato de n-(3-(4-(3-(isobutilamino)propil)-piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, sua preparação e sua utilização - Google Patents

Sais sulfato de n-(3-(4-(3-(isobutilamino)propil)-piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, sua preparação e sua utilização

Info

Publication number
PT2938597T
PT2938597T PT138157805T PT13815780T PT2938597T PT 2938597 T PT2938597 T PT 2938597T PT 138157805 T PT138157805 T PT 138157805T PT 13815780 T PT13815780 T PT 13815780T PT 2938597 T PT2938597 T PT 2938597T
Authority
PT
Portugal
Prior art keywords
propyl
diisobutylamino
piperazin
imidazol
benzo
Prior art date
Application number
PT138157805T
Other languages
English (en)
Inventor
Burlet Stéphane
Estrella Cécilia
Barrier Mathieu
Melnyk Patricia
Sergeant Nicolas
Buee Luc
Verwaerde Philippe
Original Assignee
Université De Lille 2 Droit Et Santé
Inst Nat Sante Rech Med
Alzprotect
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université De Lille 2 Droit Et Santé, Inst Nat Sante Rech Med, Alzprotect filed Critical Université De Lille 2 Droit Et Santé
Publication of PT2938597T publication Critical patent/PT2938597T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT138157805T 2012-12-27 2013-12-27 Sais sulfato de n-(3-(4-(3-(isobutilamino)propil)-piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, sua preparação e sua utilização PT2938597T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27

Publications (1)

Publication Number Publication Date
PT2938597T true PT2938597T (pt) 2016-12-09

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138157805T PT2938597T (pt) 2012-12-27 2013-12-27 Sais sulfato de n-(3-(4-(3-(isobutilamino)propil)-piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, sua preparação e sua utilização

Country Status (24)

Country Link
US (3) US9562018B2 (pt)
EP (1) EP2938597B1 (pt)
JP (1) JP6384923B2 (pt)
KR (1) KR102115060B1 (pt)
CN (1) CN105008333B (pt)
AU (2) AU2013369288B2 (pt)
BR (1) BR112015015474B1 (pt)
CA (1) CA2895285C (pt)
DK (1) DK2938597T3 (pt)
ES (1) ES2605494T3 (pt)
HK (1) HK1215582A1 (pt)
HR (1) HRP20161612T2 (pt)
HU (1) HUE030930T2 (pt)
IL (1) IL239450B (pt)
LT (1) LT2938597T (pt)
MX (1) MX363367B (pt)
NZ (1) NZ708959A (pt)
PL (1) PL2938597T3 (pt)
PT (1) PT2938597T (pt)
RS (1) RS55511B1 (pt)
RU (1) RU2655454C2 (pt)
SI (1) SI2938597T1 (pt)
WO (1) WO2014102339A1 (pt)
ZA (1) ZA201504521B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102115060B1 (ko) * 2012-12-27 2020-05-25 알즈프로텍트 N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도
EP3271335B8 (en) 2015-03-16 2019-03-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
BR112023004773A2 (pt) * 2020-10-01 2023-04-11 Alzprotect Sais sucinato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, preparação dos mesmos e uso dos mesmos
CN116419756A (zh) 2020-10-07 2023-07-11 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺硫酸盐及其溶剂合物用于治疗运动神经元疾病和神经肌肉接头病症的用途
AU2022422257A1 (en) 2021-12-20 2024-07-04 Alzprotect USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS
WO2023180537A1 (en) 2022-03-25 2023-09-28 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
AU739998B2 (en) * 1997-06-12 2001-10-25 Transgene S.A. Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy
AU6280199A (en) * 1998-09-30 2000-04-17 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
US20050020582A1 (en) * 2001-05-25 2005-01-27 Prusiner Stanley B Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
AU2003299249B2 (en) * 2002-12-23 2010-05-27 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US9044478B2 (en) * 2004-11-10 2015-06-02 Institut National De La Sante Et De La Recherche Medicale Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
KR102115060B1 (ko) * 2012-12-27 2020-05-25 알즈프로텍트 N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도

Also Published As

Publication number Publication date
AU2013369288B2 (en) 2018-02-22
US10772884B2 (en) 2020-09-15
EP2938597A1 (en) 2015-11-04
IL239450B (en) 2018-06-28
JP6384923B2 (ja) 2018-09-05
MX2015008502A (es) 2015-12-16
US20160108003A1 (en) 2016-04-21
RS55511B1 (sr) 2017-05-31
CA2895285A1 (en) 2014-07-03
KR102115060B1 (ko) 2020-05-25
SI2938597T1 (sl) 2017-03-31
AU2018202218A1 (en) 2018-04-26
RU2015130671A (ru) 2017-01-30
AU2013369288A1 (en) 2015-07-02
ZA201504521B (en) 2016-11-30
HRP20161612T2 (hr) 2017-02-24
LT2938597T (lt) 2017-01-25
ES2605494T3 (es) 2017-03-14
US10537569B2 (en) 2020-01-21
PL2938597T3 (pl) 2017-03-31
US20170151235A1 (en) 2017-06-01
IL239450A0 (en) 2015-07-30
CA2895285C (en) 2021-03-30
BR112015015474B1 (pt) 2022-04-19
KR20150105313A (ko) 2015-09-16
US20190381036A1 (en) 2019-12-19
BR112015015474A2 (pt) 2017-08-15
JP2016503813A (ja) 2016-02-08
EP2938597B1 (en) 2016-10-26
CN105008333B (zh) 2018-02-09
CN105008333A (zh) 2015-10-28
HRP20161612T1 (hr) 2017-01-27
HK1215582A1 (zh) 2016-09-02
NZ708959A (en) 2019-11-29
MX363367B (es) 2019-03-20
AU2018202218B2 (en) 2019-02-21
AU2013369288A8 (en) 2015-07-16
DK2938597T3 (en) 2017-01-09
US9562018B2 (en) 2017-02-07
HUE030930T2 (hu) 2017-06-28
WO2014102339A1 (en) 2014-07-03
RU2655454C2 (ru) 2018-05-29

Similar Documents

Publication Publication Date Title
HRP20161612T1 (hr) Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih
HUS2200046I1 (hu) Benzamidszármazékok ABL1, ABL2 és BCR-ABL1 aktivitás gátlására
HK1199022A1 (zh) -三唑- -基 苯甲酰胺及 -三唑- -基 吡啶酰胺衍生物
SG11201506093SA (en) N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
HK1206346A1 (en) N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products n-[4-(-4-)()]()
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine